Breaking News, Collaborations & Alliances

Cantargia, Patheon Biologics Sign Supply Agreement

Secures production of antibody CAN04 for clinical trials

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cantargia AB and Patheon Biologics B.V. have signed an agreement regarding future production of the antibody CAN04 (nidanilimab). CAN04 is currently in phase IIa clinical development for non-small cell lung cancer and pancreatic cancer. According to the agreement, Cantargia secures additional production capacity for future clinical trials.   The antibody CAN04 is currently investigated in a European phase IIa clinical trial for treatment of patients with non-small cell lung cancer or pancreatic ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters